Antigua and Barbuda vs Maldives: Hepatitis B surface antigen (HBsAg) prevalence
Antigua and Barbuda
0.2%
in 2024
Maldives
0.2%
in 2024
Antigua and Barbuda rank
82nd
Maldives rank
82nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Antigua and Barbuda
- Maldives
How they compare
Antigua and Barbuda currently reports 0.2% against 0.2% in Maldives, a difference of 0.0%.
Across all 10 years both countries report, Maldives has been ahead every year.
Antigua and Barbuda ranks 82nd and Maldives ranks 82nd of 194 countries.
Maldives has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.4% | 0.1% | Maldives |
| 2020s | 0.2% | 0.2% | 0.0% | Maldives |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Antigua and Barbuda or Maldives?
- Antigua and Barbuda, at 0.2% against 0.2% in Maldives as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Antigua and Barbuda and Maldives?
- 0.0%, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and Maldives?
- 10 years are reported by both, from 2015 to 2024.
- How do Antigua and Barbuda and Maldives rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Antigua and Barbuda ranks 82nd and Maldives ranks 82nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.